In this context, the presence of a few mutated subclones detectable only by high-sensitivity NGS could influence the response of the colorectal tumour to target therapy in two opposite ways: (1) they do not affect the response of the tumour to anti EGFR therapy suggesting that the detection by high sensitivity method could exclude potentially responsive patients from anti EGFR therapy and (2) they negatively affect the response to anti-EGFR therapy suggesting that higher sensitivity-genotyping method may enhance the predictive value of these molecular markers. This evidence concerns the gene EGFR and colorectal neoplasm.